Coagulation Analyzers Market to Surge to US$ 13.17 Billion by 2025 | Siemens AG, Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd.

Coagulation analyzer is a system used to measure coagulation studies such as APTT (Activated Partial Thromboplastin Time), PT (Prothrombin Time), TT (Thrombin Time), and D-Dimer test in a fast and simple way. These analyzers could provide diagnostic prevention from heart attack including blood clots by measuring various biomarkers present in the blood. Manufacturers are focusing on developing innovative diagnostic tools to improve the speed of diagnosis for patients suffering from various diseases, mostly in the emergency departments, which in turn would benefit patients to start their treatments much earlier and prevent further risks associated with these conditions. Thus, reduction in turnaround time facilitated by coagulation analyzers is expected to have a significant impact on growth of the market.

Get Quick access to Report Sample @ https://www.coherentmarketinsights.com/insight/request-sample/1255

Market Dynamics

Coagulation analyzers aid in reducing turnaround time, which aids in early diagnosis and treatment of the disease. This is expected to be a major factor for growth of the market over the forecast period. Although, manufacturers are focusing on developing accurate and sensitive innovative diagnostic products, they are also focusing on developing devices that capable of communicating and connecting with electronic medical records (EMR), and laboratory information systems without human intervention. For instance, in May 2016, Hoffmann-La Roche Ltd. launched CoaguChek INRange system in countries accepting the CE Mark. This system is a Bluetooth enabled PT/INR home health device that helps healthcare providers and patients to check their coagulation status and to monitor Vitamin K Antagonist (VKA) therapy. Furthermore, manufacturers are focusing on introducing cost-effective ready-to-use assays, including PT, APTT, D-Dimer, and antithrombin eliminating reconstitution time, acclimation time that leads to improved efficiency and better patient care.

The Global Coagulation Analyzers Market, By Product Type (Analyzers (Clinical Laboratory Analyzers, Point of Care Analyzers) and Consumables (Reagents & Kits, Point-of-care strips), By Test Type (Activated Partial Thromboplastin Time Test, Prothrombin Time Test, D-Dimer Test, Fibrinogen Test, and Other Coagulation Tests), and By End User (Hospitals, Diagnostic Laboratories, Research Institutes, and Others) was valued at US$ 2,481.78 million in 2017 and is projected to exhibit a CAGR of 9.7% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

Coagulation analyzers are used in diagnosis of bleeding disorders and thrombotic cases. The presence of coagulation analyzers these days are fully automated infuse with several advanced features to perform various functions such as cap piercing, primary tube sampling, dilution and automatic rerun. This ultimately, lowers total cost, improves the quality of patient care and assures regulatory compliance in the clinical laboratory. Instrumentation Laboratory — a Werfen company’s product — ACL TOP Family 50 series is designed for mid- to high-volume clinical laboratories, which offers the most advanced automation and quality management, for routine to specialty assays, including clotting, chromogenic, and immunological assays. These devices are highly sensitivity and offers accurate information and results thus, boosting the market growth of the coagulation analyzers over the forecast period.

Browse 22 Market Data Tables and 28 Figures spread through 150 Pages and in-depth TOC on "Coagulation Analyzers Market, by Product Type (Analyzers (Clinical Laboratory Analyzers, Point of Care Analyzers) and Consumables (Reagents & Kits, Point-of-care strips), by Test Type (Activated Partial Thromboplastin Time Test, Prothrombin Time Test, D-Dimer Test, Fibrinogen Test and Other Coagulation Tests) and by End User (Hospitals, Diagnostic Laboratories, Research Institutes and Others) - Global Forecast to 2025"

To know the latest trends and insights related to coagulation analyzers market, click the link below:
https://www.coherentmarketinsights.com/market-insight/coagulation-analyzers-market-1255

Companies are focusing on developing next generation diagnostic analyzers to help to improve specificity, accuracy, and overall productivity without making the test expensive. They are developing portable and small sized analyzers, in order to enhance their market share. These innovative analyzers offer the same results in less turnaround time making them hassle free and feasible for the operators. For instance, in July 2017, Sysmex America, Inc. launched its XN-L automated hematology analyzers in the U.S. to meet the demand of lower-volume hematology analyzers. Moreover, in 2014, Siemens Healthineer’s product Xprecia Stride Coagulation Analyzer — a handheld device — received U.S. FDA approval for reliable monitoring of oral anticoagulation therapy with warfarin, a vitamin K antagonist. Moreover, in 2015, this same analyzer, received the Red Dot award for its design quality. The Red Dot Award is the largest and most recognized international product competition in the world for product design quality. These factors are expected to augment growth of the coagulation analyzers market over the forecast period.

Key players in the market are also engaged in strategic acquisitions and collaborations to increase their product portfolios and to introduce new platform technologies. For instance, in January 2012, Roche entered into a strategic alliance with Technoclone — a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria — to further expand the company’s reagent portfolio in coagulation diagnostics. This in turn, will help the Roche to retain the market share in in-vitro diagnostics. Furthermore, in August 2015, Abbott Laboratories entered into a definitive agreement to acquire Omnilab — a middleware provider for clinical diagnostics and blood transfusion laboratories — to expand lab offerings to international markets outside the U.S.

Key Takeaways of the Coagulation Analyzers Market:

- The global coagulation analyzers market is expected to exhibit a CAGR of 9.7% over the forecast period (2017–2025). This is attributed to increasing adoption of these devices, as it provides accurate results in low turnaround time.

- Among product types, clinical laboratory analyzers segment is expected to account for the largest share in the global coagulation analyzers market over the forecast period. This is attributed to increasing use of these devices in hospitals for hematological analysis of patients on a daily basis.

- Among test types, prothrombin test segment accounted for the largest share in 2016, and this is owing to increasing incidence of cardiovascular and blood related diseases. According to Centers for Disease Control & Prevention (CDC), 2014, annually, 790,000 people in the U.S. suffer from heart attack, which indicates a potential need for immediate diagnosis and need for the early treatment

- Prevailing trend of outsourcing hemostasis tests to diagnostic centers for quick reports is expected to be factor for growth of the diagnostic laboratories segment over the forecast period.

- Some of the major players in the global coagulation analyzers market are Siemens AG, Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Instrumentation Laboratory, Sysmex Corporation, Beckman Coulter, Inc. (Danaher), Diamond Diagnostics, International Technidyne Corporation, Nihon Kohden Corporation, and Alere Inc.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.